JP2010516639A5 - - Google Patents

Download PDF

Info

Publication number
JP2010516639A5
JP2010516639A5 JP2009545828A JP2009545828A JP2010516639A5 JP 2010516639 A5 JP2010516639 A5 JP 2010516639A5 JP 2009545828 A JP2009545828 A JP 2009545828A JP 2009545828 A JP2009545828 A JP 2009545828A JP 2010516639 A5 JP2010516639 A5 JP 2010516639A5
Authority
JP
Japan
Prior art keywords
cancer
carcinoma
tumor
sarcoma
gland
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009545828A
Other languages
English (en)
Japanese (ja)
Other versions
JP5266253B2 (ja
JP2010516639A (ja
Filing date
Publication date
Priority claimed from DE102007002715A external-priority patent/DE102007002715A1/de
Application filed filed Critical
Publication of JP2010516639A publication Critical patent/JP2010516639A/ja
Publication of JP2010516639A5 publication Critical patent/JP2010516639A5/ja
Application granted granted Critical
Publication of JP5266253B2 publication Critical patent/JP5266253B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009545828A 2007-01-18 2007-12-11 Hsp90阻害剤としてのトリアゾール誘導体 Expired - Fee Related JP5266253B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102007002715.1 2007-01-18
DE102007002715A DE102007002715A1 (de) 2007-01-18 2007-01-18 Triazolderivat
PCT/EP2007/010775 WO2008086857A1 (de) 2007-01-18 2007-12-11 Triazolderivat als hsp 90 inhibitor

Publications (3)

Publication Number Publication Date
JP2010516639A JP2010516639A (ja) 2010-05-20
JP2010516639A5 true JP2010516639A5 (cg-RX-API-DMAC10.html) 2011-02-03
JP5266253B2 JP5266253B2 (ja) 2013-08-21

Family

ID=39345628

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009545828A Expired - Fee Related JP5266253B2 (ja) 2007-01-18 2007-12-11 Hsp90阻害剤としてのトリアゾール誘導体

Country Status (22)

Country Link
US (1) US8816070B2 (cg-RX-API-DMAC10.html)
EP (1) EP2102175B1 (cg-RX-API-DMAC10.html)
JP (1) JP5266253B2 (cg-RX-API-DMAC10.html)
KR (1) KR20090101381A (cg-RX-API-DMAC10.html)
CN (1) CN101583605B (cg-RX-API-DMAC10.html)
AR (1) AR064951A1 (cg-RX-API-DMAC10.html)
AU (1) AU2007344512B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0720956A2 (cg-RX-API-DMAC10.html)
CA (1) CA2675737C (cg-RX-API-DMAC10.html)
CL (1) CL2008000134A1 (cg-RX-API-DMAC10.html)
DE (1) DE102007002715A1 (cg-RX-API-DMAC10.html)
EA (1) EA015366B1 (cg-RX-API-DMAC10.html)
EC (1) ECSP099586A (cg-RX-API-DMAC10.html)
ES (1) ES2455504T3 (cg-RX-API-DMAC10.html)
MX (1) MX2009007479A (cg-RX-API-DMAC10.html)
MY (1) MY151452A (cg-RX-API-DMAC10.html)
NZ (1) NZ579069A (cg-RX-API-DMAC10.html)
PE (1) PE20090051A1 (cg-RX-API-DMAC10.html)
TW (1) TW200838502A (cg-RX-API-DMAC10.html)
UA (1) UA98320C2 (cg-RX-API-DMAC10.html)
WO (1) WO2008086857A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200905700B (cg-RX-API-DMAC10.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8742133B2 (en) * 2007-08-13 2014-06-03 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
AR077405A1 (es) 2009-07-10 2011-08-24 Sanofi Aventis Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
RS53716B1 (sr) * 2009-10-19 2015-04-30 Synta Pharmaceuticals Corp. Kombinovana terapija kancera sa hsp90 inhibitornim jedinjenjima
US9205086B2 (en) 2010-04-19 2015-12-08 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor
DE102010024338A1 (de) 2010-06-18 2011-12-22 Merck Patent Gmbh Verfahren zur Herstellung von 5-[4-(2-Methyl-phenyl)-3-hydroxy-4H-[1,2,4]triazol-5-yl]-2,4-dihydroxy-methyl-butyl-benzamid
HRP20150462T1 (hr) * 2010-10-01 2015-07-17 Taisho Pharmaceutical Co., Ltd Derivat 1,2,4-triazolona
CN103391777A (zh) * 2011-02-02 2013-11-13 普林斯顿大学理事会 作为病毒产生调节剂的去乙酰化酶调节剂
WO2013067162A1 (en) 2011-11-02 2013-05-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
AU2012332424A1 (en) 2011-11-02 2014-06-05 Synta Pharmaceuticals Corp. Combination therapy of Hsp90 inhibitors with platinum-containing agents
WO2013074594A1 (en) 2011-11-14 2013-05-23 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with braf inhibitors
CN106478531B (zh) * 2015-08-25 2019-06-28 南京华威医药科技集团有限公司 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1,2,4-三唑-3-基硫基)乙酸中间体
MX2025007723A (es) * 2018-05-14 2025-08-01 Reata Pharmaceuticals Inc Biarilamidas con grupos de azucar modificados para el tratamiento de enfermedades asociadas con la trayectoria de la proteina de choque de calor
CN115006395B (zh) * 2022-04-29 2023-03-14 佛山病原微生物研究院 一种xl888在制备用于抗腺病毒感染的药物中的用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968921A (en) 1997-10-24 1999-10-19 Orgegon Health Sciences University Compositions and methods for promoting nerve regeneration
WO1999051223A1 (en) 1998-04-03 1999-10-14 University Of Pittsburgh Of The Commonwealth System Of Higher Education Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke
AU776652B2 (en) 1999-03-12 2004-09-16 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Method of inhibiting a chaperone protein
WO2001072779A1 (en) 2000-03-24 2001-10-04 Duke University Characterization of grp94-ligand interactions and purification, screening, and therapeutic methods relating thereto
US6887853B2 (en) 2000-06-29 2005-05-03 The Trustees Of Boston University Use of geldanamycin and related compounds for treatment of fibrogenic disorders
EP1322325A4 (en) 2000-07-20 2004-09-15 Merck & Co Inc INHIBITION OF PROCESSING AND REPLICATION OF HEPATITIS C VIRUS
US6946456B2 (en) 2000-07-28 2005-09-20 Sloan-Kettering Institute For Cancer Research Methods for treating cell proliferative disorders and viral infections
US7439359B2 (en) 2000-11-02 2008-10-21 Sloan-Kettering Institute For Cancer Research Small molecule compositions for binding to hsp90
WO2003041643A2 (en) 2001-11-09 2003-05-22 Conforma Therapeutics Corporation Hsp90-inhibiting zearalanol compounds and methods of producing and using same
JP4399265B2 (ja) 2001-12-21 2010-01-13 ヴァーナリス(ケンブリッジ)リミテッド 3,4−ジアリールピラゾール、および癌の治療におけるそれらの使用
GB0228417D0 (en) 2002-12-05 2003-01-08 Cancer Rec Tech Ltd Pyrazole compounds
GB0229618D0 (en) 2002-12-19 2003-01-22 Cancer Rec Tech Ltd Pyrazole compounds
US20050054625A1 (en) 2003-05-30 2005-03-10 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with nuclear export inhibitors
US20050026893A1 (en) 2003-05-30 2005-02-03 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with immunosuppressants
US20050020557A1 (en) 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with enzyme inhibitors
US7691838B2 (en) 2003-05-30 2010-04-06 Kosan Biosciences Incorporated Method for treating diseases using HSP90-inhibiting agents in combination with antimitotics
US20050020556A1 (en) 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with platinum coordination complexes
US20050054589A1 (en) 2003-05-30 2005-03-10 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with antibiotics
US20050020534A1 (en) 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with antimetabolites
ES2594874T3 (es) * 2004-11-18 2016-12-23 Synta Pharmaceuticals Corp. Compuestos de triazol que modulan la actividad de HSP90
DE102005007304A1 (de) 2005-02-17 2006-08-24 Merck Patent Gmbh Triazolderivate

Similar Documents

Publication Publication Date Title
Sun et al. Natural berberine-hybridized benzimidazoles as novel unique bactericides against Staphylococcus aureus
Gupta et al. Destabilization potential of phenolics on Aβ fibrils: Mechanistic insights from molecular dynamics simulation
Xia et al. Synthesis and biological activities of oxazolidinone pleuromutilin derivatives as a potent anti-MRSA agent
Chai et al. Potential succinate dehydrogenase inhibitors bearing a novel pyrazole-4-sulfonohydrazide scaffold: molecular design, antifungal evaluation, and action mechanism
Łączkowski et al. Thiazoles with cyclopropyl fragment as antifungal, anticonvulsant, and anti-Toxoplasma gondii agents: synthesis, toxicity evaluation, and molecular docking study
WO2007130383A3 (en) Compositions and treatments using pyridazine compounds and secretases
MX2010002353A (es) Amidas heterociclicas utiles para tratamiento de cancer y psoriais.
MXPA05010937A (es) Derivados de fenilalanina n-(1,3-tiazol-2-il)amino)carbonil)fenil)sulfonil) y compuestos relacionados para el tratamiento de diabetes.
Ali et al. Dihydropyrazole derivatives act as potent α-amylase inhibitors and free radical scavengers: synthesis, bioactivity evaluation, structure–activity relationship, ADMET, and molecular docking studies
Lutfiya et al. Molecular docking and interactions between vascular endothelial growth factor (VEGF) receptors and phytochemicals: An in-silico study
TW200630327A (en) Substituted phenylalkanoic acids
DE602004016850D1 (de) Pyrazoloä3,4-büpyridin-6-one als gsk-3 inhibitoren
BRPI0510206A (pt) método de identificação de fenótipo, célula isolada, métodos de identificação de agentes, agentes, agentes terapêuticos, método de avaliação de agente terapêutico, composição farmacêutica, métodos de tratamento, prevenção ou melhoria de disfunções e métodos de modulação
JP5759000B2 (ja) 肝疾患治療の薬物の製造におけるジインドリルメタン及びその前駆体並びにその誘導体の応用
Ozdemir et al. Synthesis, anticonvulsant and antimicrobial activities of some new [1-(2-naphthyl)-2-(pyrazol-1-yl) ethanone] oxime ethers
JP2019501948A (ja) 化学療法で誘導される末梢神経障害の治療に使用するためのil−8阻害剤
Sharma et al. Curcumin analogs as anti-cathepsins agents: Designing, virtual screening, and molecular docking analysis
Malik et al. Cancer-Fighting Isoxazole Compounds: Sourcing Nature's Potential and Synthetic Advancements-A Comprehensive Review
Rizvi et al. The flavonoid hesperidin methyl chalcone as a potential therapeutic agent for cancer therapy: molecular docking, in vitro cytotoxicity, and in vivo antitumor activity
GB2467561A (en) Dual calpain-ROS inhibitors
Brahmbhatt et al. Synthesis, characterization, antibacterial and antioxidant potency of N-substituted-2-sulfanylidene-1, 3-thiazolidin-4-one derivatives and QSAR study
EP1817312A4 (en) MACROCYCLIC AMINIOPYRIDYL BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF MORBUS ALZHEIMER
NO20065717L (no) Substituerte N-arylbenzamider og beslektede forbindelser for behandling av amyloidsykdommer og synukleinopatier.
WO2009078587A2 (en) Composition for prevention and treatment of cancer containing triazolyl-thio-ethanone derivatives inhibiting activity of protein phosphatases or pharmaceutically acceptable salts thereof as an active ingredient
WO2005094236A9 (en) Activation of hypoxia-inducible gene expression